Business Context and Reporting Period
This Form 10-Q covers DAXOR CORP for the quarter ended March 31, 1998. The company operates clinical laboratories, including blood and semen banking facilities, and is developing a Blood Volume Analyzer. Operations are currently constrained by ongoing legal disputes with the New York State Department of Health and the New York Blood Center.
Key Financial Metrics
| Metric | Q1 1998 | Q1 1997 |
|---|---|---|
| Total Revenues | $825,525 | $864,610 |
| Operating Revenues | $94,529 | $150,282 |
| Net Income (Loss) | $(236,455) | $291,976 |
| Net Income Per Share | $(0.05) | $0.06 |
| Cash and Equivalents | $136,131 | $111,186 |
| Marketable Securities (Fair Value) | $41,858,891 | $40,347,085 |
| Total Assets | $43,242,160 | $41,322,592 |
| Total Liabilities | $8,038,903 | $8,404,868 |
| Shareholders' Equity | $35,203,257 | $32,917,724 |
| Loans Payable | $1,244,204 | $2,494,639 |
Material Changes
- Profitability: The company reported a net loss of $236,455, a reversal from a net income of $291,976 in the prior year. This was driven by a decline in operating revenues and a significant increase in interest expense.
- Operating Revenue: Operating revenues dropped 37% to $94,529 due to legal restrictions preventing the acquisition of new clients for blood and semen banking services.
- Interest Expense: Net interest expense surged to $179,510 from $18,482 in the prior year.
- Investment Portfolio: Marketable securities increased in fair value to $41.86 million, resulting in a net unrealized holding gain of approximately $18.3 million (pre-tax), which significantly bolsters shareholders' equity.
- Liquidity: Cash increased by $75,363 during the quarter, primarily due to financing activities involving the reissuance of treasury stock ($1.49 million) and a reduction in broker loans.
Outlook, Risks, and Management Commentary
- Legal Contingencies: The company is engaged in a $55 million action against the New York State Department of Health and a $100 million RICO/Anti-Trust suit against the New York Blood Center. A federal judge recently ruled against Daxor in the RICO action, which is currently under appeal. Management considers the outcome of these suits unpredictable.
- Operational Strategy: Due to regulatory opposition to private blood banking, management is considering moving semen banking operations out of New York State and discontinuing blood banking operations. Future focus will shift to the marketing and sales of the Blood Volume Analyzer.
- Capital Resources: The company states it has adequate liquid capital to sustain current operations and market the Blood Volume Analyzer. However, a nationwide expansion of blood banking would require additional capital.
- Unusual Items: The financial statements reflect a significant unrealized gain on available-for-sale securities ($12.1 million after-tax) included in equity, which masks the operating loss.
Investor Verification Checklist
- Verify the status and potential settlement value of the $55 million Court of Claims action and the $100 million RICO suit.
- Confirm the timeline for FDA clearance and commercial rollout of the Blood Volume Analyzer.
- Assess the sustainability of the investment portfolio's unrealized gains versus the company's operating cash burn.
- Review the terms of the $1.24 million in loans payable, specifically the 7.5% interest rate and collateral requirements.
- Monitor any regulatory updates regarding the New York State Department of Health's stance on private blood and semen banking.